Neurogenic Transdifferentiation of Human Adipose-derived Stem Cells? A Critical Protocol Reevaluation with Special Emphasis on Cell Proliferation and Cell Cycle Alterations
Overview
Cell Biology
Authors
Affiliations
Adipose-derived stem cells (ASCs) are reported to display multilineage differentiation potential, including neuroectodermal pathways. The aim of the present study was to critically re-evaluate the potential neurogenic (trans-)differentiation capacity of ASCs using a neurogenic induction protocol based on the combination of isobutylmethylxanthine (IBMX), indomethacin and insulin. ASCs isolated from lipo-aspirate samples of five healthy female donors were characterized and potential neurogenic (trans-)differentiation was assessed by means of immunohistochemistry and gene expression analyses. Cell proliferation and cell cycle alterations were studied, and the expression of CREB/ATF transcription factors was analyzed. ASCs expressed CD59, CD90 and CD105, and were tested negative for CD34 and CD45. Under neurogenic induction, ASCs adopted a characteristic morphology comparable to neur(on)al progenitors and expressed musashi1, β-III-tubulin and nestin. Gene expression analyses revealed an increased expression of β-III-tubulin, GFAP, vimentin and BDNF, as well as SOX4 in induced ASCs. Cell proliferation was significantly reduced under neurogenic induction; cell cycle analyses showed a G2-cell cycle arrest accompanied by differential expression of key regulators of cell cycle progression. Differential expression of CREB/ATF transcription factors could be observed on neurogenic induction, pointing to a decisive role of the cAMP-CREB/ATF system. Our findings may point to a potential neurogenic (trans-)differentiation of ASCs into early neur(on)al progenitors, but do not present definite evidence for it. Especially, the adoption of a neural progenitor cell-like morphology must not automatically be misinterpreted as a specific characteristic of a respective (trans-)differentiation process, as this may as well be caused by alterations of cell cycle progression.
Chang M, Hong Y, Hsu C, Harn H, Huang B, Liu Y Stem Cells Transl Med. 2024; 13(3):293-308.
PMID: 38173411 PMC: 10940829. DOI: 10.1093/stcltm/szad090.
Sachana M, Willett C, Pistollato F, Bal-Price A Reprod Toxicol. 2021; 103:159-170.
PMID: 34147625 PMC: 8279093. DOI: 10.1016/j.reprotox.2021.06.006.
Differentiation of Mesenchymal Stem Cells to Neuroglia: in the Context of Cell Signalling.
George S, Hamblin M, Abrahamse H Stem Cell Rev Rep. 2019; 15(6):814-826.
PMID: 31515658 PMC: 6925073. DOI: 10.1007/s12015-019-09917-z.
Jia Y, Zhao Y, Wang L, Xiang Y, Chen S, Ming C Am J Transl Res. 2016; 8(5):2059-69.
PMID: 27347314 PMC: 4891419.
Szepes M, Benko Z, Cselenyak A, Kompisch K, Schumacher U, Lacza Z Stem Cells Int. 2013; 2013:178346.
PMID: 23853609 PMC: 3703900. DOI: 10.1155/2013/178346.